Endocyte, Inc. (NASDAQ:ECYT) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

ECYT has been the topic of several other reports. Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $2.00 to $7.00 in a research report on Tuesday, October 3rd. Finally, Cowen and Company reissued a “hold” rating on shares of Endocyte in a research report on Monday, October 2nd.

Shares of Endocyte (NASDAQ:ECYT) opened at $4.60 on Tuesday. Endocyte has a fifty-two week low of $1.17 and a fifty-two week high of $6.55.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The business had revenue of $0.03 million during the quarter. Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. Endocyte’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the business earned ($0.21) EPS. analysts expect that Endocyte will post -1.24 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Endocyte, Inc. (ECYT) Stock Rating Lowered by ValuEngine” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/13/endocyte-inc-ecyt-stock-rating-lowered-by-valuengine.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of Endocyte by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock valued at $369,000 after acquiring an additional 6,469 shares during the last quarter. FMR LLC grew its stake in Endocyte by 0.7% during the 1st quarter. FMR LLC now owns 3,509,035 shares of the biopharmaceutical company’s stock worth $9,018,000 after buying an additional 24,625 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Endocyte by 34.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Endocyte by 26.7% during the 1st quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 28,110 shares during the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in Endocyte by 57.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 162,329 shares of the biopharmaceutical company’s stock worth $417,000 after buying an additional 59,454 shares during the last quarter. Institutional investors and hedge funds own 25.47% of the company’s stock.

Endocyte Company Profile

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.